Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (641-650 of 666) with videos related to

Pageof 67
Sort By:
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 4, 2022
Assessing Global Kidney Nutrition CareAngela Yee-Moon Wang, Ikechi G Okpechi, Feng Ye, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 7, 2025
Rationale and design of the Renal Lifecycle Trial assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney DiseaseWisanne M Bakker, Hiddo J L Heerspink, Stefan P Berger, et al.
JAMA|June 5, 2026
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical TrialBrendon L Neuen, Vlado Perkovic, Rajiv Agarwal, et al.
European Heart Journal|April 22, 2017
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpointsPatrick Rossignol, Rajiv Agarwal, Bernard Canaud, et al.
Hypertension (Dallas, Tex. : 1979)|February 15, 2021
Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?Antonia Vlahou, Dara Hallinan, Rolf Apweiler, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Pageof 67

Showing results (641-650 of 666) with videos related to

Sort By:
Pageof 67
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 4, 2022
Assessing Global Kidney Nutrition CareAngela Yee-Moon Wang, Ikechi G Okpechi, Feng Ye, et al.
Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 7, 2025
Rationale and design of the Renal Lifecycle Trial assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney DiseaseWisanne M Bakker, Hiddo J L Heerspink, Stefan P Berger, et al.
JAMA|June 5, 2026
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical TrialBrendon L Neuen, Vlado Perkovic, Rajiv Agarwal, et al.
European Heart Journal|April 22, 2017
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpointsPatrick Rossignol, Rajiv Agarwal, Bernard Canaud, et al.
Hypertension (Dallas, Tex. : 1979)|February 15, 2021
Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?Antonia Vlahou, Dara Hallinan, Rolf Apweiler, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Pageof 67